Стан ДНК-метилювання гена глутатіон-S-трансферази P1 (GSTP1) у хворих на рак сечостатевої системи
Aims. Epigenetic changes are observed in different types of cancers and can offer a suitable markers for diagnostic uses. The changes in glutathione-S-transferase P1 gene (GSTP1) expression may be involved in the initiation and progression of urogenital malignancies and are often caused by an aberrant DNA-methylation of its CpG-island-promoter. The purpose of current study was to analyze DNA-methylation status of GSTP1 promoter using genomic DNAs from the cancer-associated night urea cells from the patients with kidney, bladder and prostate tumors. Methods. Genomic DNA was extracted from the blood and night urea samples from the urogenital malignancy patients and healthy samples (placenta, fetal blood). Bisulfite conversion of genomic DNA with following methylation-specific PCR were used to DNA methylation GSTP1 promoter study. Results. We have shown that GSTP1 CpG-island-promoter is aberrantly hypermethylated in genomic DNA, extracted from the night urea of patients with urogenital malignancies (kidney, bladder, prostate tumors). In contrast, in the peripheral blood of these cancer patients and healthy controls GSTP1 CpG-promoter really retained physiological unmethylated state. Conclusions. Aberrant GSTP1 promoter DNA-methylation may be used as an available biomarker for the development of non-invasive diagnostic of urogenital malignancies in the urea biosamples.
Keywords: GSTP1 gene, DNA-methylation, urogenital malignancies, DNA bisulfite -methylation-specific PCR.